647 related articles for article (PubMed ID: 25589779)
1. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR
JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
6. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
7. SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease.
Weiner S; Sauer M; Brinkmalm G; Constantinescu J; Constantinescu R; Gomes BF; Becker B; Nellgård B; Dalla K; Galasko D; Zetterberg H; Blennow K; Gobom J
Alzheimers Dement; 2023 Oct; 19(10):4609-4618. PubMed ID: 36946611
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
[TBL] [Abstract][Full Text] [Related]
9. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
10. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
Ge F; Ding J; Liu Y; Lin H; Chang T
Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
[TBL] [Abstract][Full Text] [Related]
13. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
14. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.
Jabbari E; Woodside J; Guo T; Magdalinou NK; Chelban V; Athauda D; Lees AJ; Foltynie T; Houlden H; Church A; Hu MT; Rowe JB; Zetterberg H; Morris HR
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):768-773. PubMed ID: 30867224
[TBL] [Abstract][Full Text] [Related]
15. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
[TBL] [Abstract][Full Text] [Related]
16. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
[TBL] [Abstract][Full Text] [Related]
18. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
[TBL] [Abstract][Full Text] [Related]
19. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
